期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心肌脂肪酸氧化抑制剂的研究进展 被引量：1

Advances in study of myocardial fatty acid oxidation inhibitor
下载PDF
导出
摘要 随着人们对缺血心肌能量代谢改变的深入研究,发现抑制脂肪酸的氧化可改善组织氧利用的有效性,为缺血性心脏病的改善和预后提供了新的治疗措施。本文综述了心肌脂肪酸氧化抑制剂的药理效应、作用机制以及此类药物的研究进展。 With the development of study in changes of ischemic cardiac energy metabolism deeply, new treatment strategies decreasing the use of fatty acids to increase the heart＇s oxygen availability was proposed. This review focuses on the pharmacological effects, the mechanism of actions and the advance of myocardial fatty acid oxidation inhibitor.
作者 杨莹 薛霞 刘兆平
机构地区 山东中医药大学教学实验中心 山东大学新药评价中心
出处 《齐鲁药事》 2008年第9期549-551,共3页 qilu pharmaceutical affairs
关键词 脂肪酸氧化抑制剂 缺血性心脏病 代谢性药物 肉毒碱 Fatty acid oxidation inhibitor ischemic heart disease metabolic agent carnitine
分类号 R972.6 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1Siddiqui MA,Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs, 2006,66 (5) : 693-710.
  • 2Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail, 2002,8 (6) :416-422.
  • 3Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amLodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized eontrolled trial, JAMA,2004,291(3):309-316.
  • 4Kantor PF,Lucien A,Kozak R,et al. The antianginal drug trimetazldine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long--chain 3-- ketoacyl coenzyme A thiolase. Circ Res, 2000,86 (5) : 580- 588.
  • 5Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina:a meta--analysis of randomized,double--blind, controlled trials. Coron Artery Dis, 2003,14(2) : 171-179.
  • 6Lloyd S, Broeks C, Chatham JC. Differential modulation of glucose,lactate, and pyruvate oxidation by insulin and diehloroacetare in the rat heart. Am J Physiol Heart Circ Physiol, 2003,285 (1):H163.
  • 7Schmitz FJ, Rosen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoy I transferase inhibitor Etomoxir. Horm Metab Res, 1995, 27 (12) :515-522.
  • 8Schmidt--Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) ,2000,99(1) :27-35.
  • 9Kennedy JA, Unger SA, Horowitz JD. Inhibition of earnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol, 1996,52(2) : 273-280.
  • 10Stewart S, Voss DW, Northey DL, et al. Relationship between plasma perhexiline concentration and symptomatic stalus during short-- term perhexiline therapy. Ther Drug Monit, 1996, 18 (6):635-639.

同被引文献17

  • 1Parang P,Singh B,Arora R.Metabolic modulators for chronic cardiac ischemia[J].J Cardiovasc Pharmacol Ther,2005,10(4):217-223.
  • 2Pauly DF,Pepine CJ.Ischemic heart disease:Metabolic approaches to management[J].Clin Cardiol,2004,27(8):439-441.
  • 3Chaitman BR.Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions[J].Circulation,2006,113(20):2462-2472.
  • 4Stone PH,Chaitman BR,Stocke K,et al.The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease[J].J Am Coll Cardiol,2010,56(12):934-942.
  • 5Wang JX,Maruyama K,Murakami M,et al.Antianginal effects of ranolazine in various experimental models of angina[J].Arzneimittelforschung,1999,49(3):193-199.
  • 6Chandler MP,Stanley WC,Morita H,et al.Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure[J].Circ Res,2002,91(4):278-280.
  • 7Nanda S,Martinez MW,Dey T.Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure[J].J Am Coll Cardiol,2010,56(10):822.
  • 8Singh BN,Wadhani N.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs[J].J Cardiovasc Pharmacol Ther,2004,9(Suppl 1):85-97.
  • 9Zacharowski K,Blackburn B,Thiemermann C.Ranolazine,a partial fatty acid oxidation inhibitor,reduces myocardial infarct size and cardiac troponin T release in the rat[J].Eur J Pharmacol,2001,418(1-2):105-110.
  • 10Morrow DA,Scirica BM,Karwatowska-Prokopczuk E,et al.Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes:The MERLIN-TIMI 36 randomized trial[J].J Am Med Assec,2007,297(16):1775-1783.

引证文献1

二级引证文献2

齐鲁药事
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部